TAT congresses are of interest to a broad range of professionals, including everyone in the academic environment, industry (pharma, biotech, diagnostic) and drug regulatory agencies, involved in the discovery, development and evaluation of innovative cancer therapeutics. Clinicians working in various fields of medicine, including medical oncology, hematology, immunology, pathology, pharmacology, as well as non-clinicians working in translational cancer research, will find TAT 2017 a very worthwhile event to attend.
Clinicians and scientists conducting clinical and/or translational cancer research are encouraged to take the opportunity to present their work as a proffered paper or poster during the congress. Submit your abstract(s) before the deadline. In past TAT Congress, 80-85% of submitted abstracts was scheduled for presentation, 5-10% as oral papers.